Synthesis of a Precursor to LY2140023

Significance: LY2140023 is a conformationally restricted glutamic acid analogue that is an mGlu2/3 receptor agonist. It entered phase II clinical trials for the treatment of schizophrenia. The following synthesis was used to deliver over one metric ton of the key intermediate **K**.

SYNFACTS Contributors: Philip Kocienski
Synfacts 2012, 8(2), 0121 Published online: 19.01.2012
DOI: 10.1055/s-0031-1289963; Reg-No.: K07611SF

Comment: Whilst the later steps are described on large scale, the earlier steps, especially the critical carbene insertion reaction leading to cyclopropane **B**, is reported on a small scale. A large-scale (206 mol) hydroboration of **B** using $\text{BH}_3\text{-THF}$ complex is described.